Zydax performs well in efficacy study

|By:, SA News Editor

In a large-scale study assessing the efficacy of Parnell Pharmaceutical Holdings' (PARN -4%) Zydax (sulfate ester) for the treatment of the clinical symptoms of canine osteoarthritis, 54% of the dogs treated with Zydax exhibited at least a 2.5-point reduction in PSS or PIS scores compared to 35% on placebo. The results were statistically significant (p = 0.01).

The company intends to commence a pivotal efficacy trial in October and expects to report results in 1H 2015.